News
PRTA shares drop 22% after ending birtamimab development as a phase III study fails to meet primary or secondary endpoints in AL amyloidosis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback